AI, DNA, And The Search For Preventive Health

At Biohacker Summit In Helsinki, Joe Cohen Argued That The Future Of Medicine Lies In Treating The Whole System Before Disease Takes Hold

On 2 July 2024 at the Biohacker Summit in Helsinki, Finland, Joe Cohen took the stage with a disarming joke and a serious proposition: that health could no longer be understood symptom by symptom, organ by organ, or crisis by crisis. Instead, Cohen, founder and chief executive of SelfDecode, SelfHacked and LabTestAnalyzer, made the case for a more sweeping model, one in which artificial intelligence, genetic data, biomarker testing and lifestyle analysis converge into a single map of human risk.

His talk, titled How to Use AI & Precision Health to Achieve Superhuman Results, was less a hymn to technological novelty than a critique of the fragmentation that still defines much of modern healthcare. The old way, he suggested, encouraged people to chase one problem at a time: better mood, less fatigue, improved digestion, stronger focus. But the body, Cohen insisted, did not operate in isolated compartments.

“The body is very fascinating in how much it could change,” he said.

A Rebellion Against One Symptom At A Time

Cohen’s central argument rested on interconnectedness. People tended to arrive with one pressing complaint, he said, but further questioning often revealed a web of neglected issues: skin problems, gut disturbances, low energy, anxiety, allergies, poor recovery, sleep disruption. The apparent headline symptom was often only one thread in a larger physiological story.

His answer was totality. Not just symptoms, but conditions, goals, inherited risks, blood markers and life events had to be considered together. Precision health, in his framing, meant resisting the temptation to treat a single complaint in isolation.

“You have to look at things in a totality,” Cohen said. “You have to first take all the information into account, and you're usually going to have a high risk for a bunch of things that won't necessarily present now, but they can present in the future.”

That future-facing emphasis ran through the presentation. Cohen described chronic disease not as a sudden event, but as a slow accumulation, often measurable long before formal diagnosis arrives.

Why AI Sits At The Centre Of The Pitch

For Cohen, AI was not simply a fashionable add-on to health technology. It was the engine that made scale possible. A meaningful precision-health model, he argued, could not rely on a handful of genetic markers or a static PDF report. It needed to process vast numbers of variables and then translate them into advice a person could actually use.

“AI is also needed for a precision health GPT... we can look at all of your data and then give you an intelligent answer based on your data, not based on generic information online,” he said.

That distinction mattered. Generic health content, however polished, could only offer broad probabilities. Cohen’s claim was that AI-driven tools could move from population-level guidance to individual interpretation, drawing on DNA variants, lab results, questionnaires and risk rankings all at once.

He was particularly dismissive of consumer genetics services that spotlight only a small number of variants. In his account, such simplification missed the complexity of biology and risked offering false confidence. The challenge was not merely collecting data, but integrating it intelligently.

The Biomarker State Of The Body

If DNA formed the foundation of Cohen’s model, biomarkers were its present tense. Genetic testing could indicate predisposition, but lab work revealed what was happening now. In that sense, genes set the stage while biomarkers tracked the performance.

Cohen said he tested hundreds of biomarkers regularly and argued that optimal health required attention not only to abnormal values, but to suboptimal ones as well. A result that sat within a conventional reference range might still fall short of what long-term health demanded.

This was the language of prevention rather than rescue. It was also an implicit rebuke to systems that intervene only once pathology becomes undeniable.

“Every disease, chronic disease, they take a long time to develop,” Cohen said. “You need to start early on in preventing them and measuring all the lab tests that are related to each of these things that you're at high risk for.”

Longevity As Risk Management

One of the sharpest moments in the talk came when Cohen reframed longevity not as an abstract aspiration, but as a practical exercise in identifying vulnerabilities early and acting before they harden into illness.

“Longevity is really about identifying what your top risks are and then preventing them,” he said. “So if you have a high risk for Alzheimer’s, if you try to treat Alzheimer’s once you have it, good luck. Very difficult.”

This was a stark formulation, but an effective one. It captured the underlying philosophy of the presentation: that medicine too often arrives late, after mechanisms have become damage and damage has become disease. Precision health, as Cohen presented it, promised a reversal of that timeline.

In this schema, the point was not merely to live longer. It was to live with more information, more foresight and, ideally, fewer avoidable collapses.

Technology, Supplements, And The Promise Of Personalisation

Cohen also spoke in practical terms about action plans, supplements and behavioural changes, stressing the importance of prioritisation. A common failure, he suggested, was not only taking too many interventions, but forgetting why each had been introduced. Without a clear rationale, people abandoned useful routines, drifted between regimens and lost continuity.

His answer was systematic tracking: know the reason for each supplement, connect it to specific risks or markers, and revise the plan as fresh data arrives. He described his own experience with additions such as chromium, citrulline and saffron as examples of how a more integrated view of symptoms, labs and genetic predispositions could reveal unexpected benefits.

It was a telling detail. Beneath the rhetoric of AI and big data, the appeal was ultimately intimate. The promise was not that machines would replace judgement, but that they might help people see themselves more clearly.

The Seduction And The Challenge Of Total Health

Cohen’s presentation at Biohacker Summit captured a wider mood in contemporary wellness and health technology: impatience with generic advice, distrust of reactive medicine, and a deepening faith that enough data, properly processed, can produce a better life.

Yet the talk also illuminated the scale of the ambition. To measure extensively, analyse continuously and personalise relentlessly is to imagine health as an ongoing computation. It is an alluring idea, especially for those failed by blunt clinical categories. But it also places extraordinary weight on interpretation, software design and the assumption that more data will necessarily lead to better decisions.

Still, in Helsinki, Cohen’s message landed with clarity. The future he described was one in which prevention became hyper-personal, risk became legible, and the body was treated less as a series of separate complaints than as a dynamic system.

The argument was simple enough to outlast the jargon: if disease develops slowly, then health must be managed early, broadly and with greater precision than most people have ever been offered.

Frequently asked questions

What is Joe Cohen's argument against symptom-by-symptom care?

That people arrive with one pressing complaint, but further questioning usually reveals a web of neglected issues: skin problems, gut disturbances, low energy, anxiety, allergies, poor recovery and disrupted sleep. The headline symptom is one thread in a larger physiological story.

Why does AI sit at the centre of his model?

Because scale. Cohen, founder of SelfDecode, argued that a meaningful precision-health model cannot rely on a handful of genetic markers or a static report. It has to process vast numbers of variables and translate them into advice a person can actually use.

How does he treat lab results?

Cohen said he tests hundreds of biomarkers regularly and argued that optimal health requires attention not only to abnormal values but to suboptimal ones. Genes set the stage, in his framing, while biomarkers track the present-tense performance.

About the event

This recap is part of the Biohacker Summit 2024 Helsinki series, recorded in Helsinki on 2 and 3 July 2024. Read the summary of the whole event or join the next edition, HOLOLIFE Summit 2026 Amsterdam, on 14 and 15 November 2026.